

☐ Order this document

I Chuan Hsueh Pao 1992;19(4):294-7

[Molecular cytogenetic study of an extra small chromosome].

[Article in Chinese]

Fu S, Fu H, Xiao H, Song X, Chen J, Gao C, Qiu H, Cheng Z

People's Hospital of Hainan Province, Haikou.

An extra small chromosome was observed in a three-generation family. Eight members of this family were involved, but their phenotypes were normal. Molecular cytogenetic study was carried out, using cytogenetic methods and chromosome in situ hybridization with 3H-labelled rDNA probe. The results showed that this chromosome was from the short arm of chromosome of D/G group. The origin and genetic effects of this chromosome and fertility of the carriers were also discussed were also discussed briefly.

PMID: 1466910, UI: 93103732

Save the above report in Macintosh Text format

order documents on this page through Loansome Doc

Search Result

Rank 1 of 2

Database WPI

(c) 1999 Derwent Info Ltd. All rights reserved.

198738

New DNA fragment contg. centromeric nucleotide sequence - and derived vectors, allowing foreign genes to be maintained in transgenic animals Patent Assignee: INSERM INST NAT SANTE & RECH MED (INRM)

Inventor: CUZIN F; LEOPOLD P; RASSOULZAD M; VAILLY J

Number of Countries: 014 Number of Patents: 003

Patent Family:

Week Patent No Kind Date Applicat No Kind Date Main IPC 198738 B FR 2593827 A 19870807 FR 861391 A 19860131 EP240373 A 19871007 EP 87400206 A 19870129 198740 198749 JP 62248491 A 19871029 JP 8719682 A 19870131

Priority Applications (No Type Date): FR 861391 A 19860131

Patent Details:

Kind Lan Pg Filing Notes Application Patent

FR 2593827 A 12

EP240373 A F

Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE Abstract (Basic): FR 2593827 A

- New DNA fragments(I) contain a centromeric nucleotide sequence (cen) which ensures regular segregation, at the moment of mitosis or meiosis, of the ori sequences necessary for replication in the autonomous state. Also new are circular auto-nomous vectors contg. (I) plus one or more relevant genes and a vector sequence.
- (I) are isolated by cloning from circular vectord obtd. following expression of poloma virus T antigen. The cloning process comprises 0) defining the restriction map of the vector; (2) identifying fragments contg. cellular sequences (e.g. by hybridisation); (3) purifying the required fragment (e.g. by electrophoresis), and opt. (4) repairing at least one end of the fragment then attachment of vector sequences. These vector sequences can act as a shuttle between the transgenic animal and a bacterial or yeast host.

USE/ADVANTAGE - The vectors are useful for transmitting and maintaEP240373A P EP48081 FP240373A T 3 Thl Rof occ grown 1 the

10 Title Terms: NEW; DNA; FRAGMENT; CONTAIN; NUCLEOTIDE; SEQUENCE; DERIVATIVE; VECTOP; ALLOW; FORFIGN; GENF; MAINTAIN; TRANS FRUS; ANIMAL

The state of the s

Index Terms/Additional Words: DEOXYRIBONUCLEIC; ACID

Derwent Class: B04; D16

International Patent Class (Additional): C07H-021/04; C12N-015/00

File Segment: CPI

Manual Codes (CPI/A-N): B04-B04A1; D05-H12

Chemical Fragment Codes (M1):
 01 M423 M710 M903 Q233 V753

END OF DOCUMENT



Search Result Rank 3 of 5

Database WPI

(c)1999 Derwent Info Ltd. All rights reserved.

Transposition construct for introducing genes into eukaryotic cell genome - includes a mobile gene element carrying the required gene for site-specific integration into ribosomal DNA, partic. for use in gene therapy.

Patent Assignee: TRANSGENE SA (TRGE)

Inventor: JACOBS E

Number of Countries: 021 Number of Patents: 006

Patent Family:

Patent No Kind Date Applicat No Kind Date Main IPC Week
FR 2703996 A1 19941021 FR 934530 A 19930416 C07H-021/04 199442 B
WO 9424300 A1 19941027 WO 94FR419 A 19940414 C12N-015/90 199442
AU 9465719 A 19941108 AU 9465719 A 19940414 C12N-015/90 199507
EP 694072 A1 19960131 EP 94913647 A 19940414 C12N-015/90 199609
WO 94FR419 A 19940414

JP 8508878 W 19960924 JP 94522836 A 19940414 C12N-015/09 199704

WO 94FR419 A 19940414

AU 686156 B 19980205 AU 9465719 A 19940414 C12N-015/90 199813

Priority Applications (No Type Date): FR 934530 A 19930416

Cited Patents: 3.Jnl.Ref; EP 485701; US 4670388; WO 8803562; WO 8803563; WO 9207950

Patent Details:

Patent Kind Lan Pq Filing Notes Application Patent

FR 2703996 A1 40

WO 9424300 A1

Designated States (National): AU CA JP US

Designated States (RegionLI LU MC

NL PT SE

JP 8508878 W 37 Based on WO 9424300 AU 686156 B Previous Publ. AU 9465719

Based on WO 9424300

Abstract (Basic): FR 2703996 A

Transposition construct (A) for transfer of a greatfit factor of

USE - (A) are used for gene therapy: (a) to generate antisense ENA corresponding to a pathogen gene transcript, e.g. from a bacterial, viral or ramally more and a pathogen services of the contract of the co

is absent from or expressed abnormally in, the host, e.g. a cytokine, membrane receptor, enzyme, enzyme inhibitor, coagulation factor, tumour suppressor, antigen, etc.

ADVANTAGE - (A) can deliver (I) to a defined, non-essential region of the host gene (esp. rRNA 28S, 18S or 5-8S genes). By introducing (I) into the integral sequence of MGE uncontrolled proliferation of IS is prevented.

Dwg.0/1

Title Terms: TRANSPOSE; CONSTRUCTION; INTRODUCING; GENE; EUKARYOTIC; CELL; GENOME; MOBILE; GENE; ELEMENT; CARRY; REQUIRE; GENE; SITE; SPECIFIC; INTEGRATE; RIBOSOME; DNA; GENE; THERAPEUTIC

Derwent Class: B04; D16

International Patent Class (Main): C07H-021/04; C12N-015/09; C12N-015/90

International Patent Class (Additional): A61K-031/70; A61K-037/54;

A61K-048/00; C12N-005/10; C12N-009/22; C12N-015/55; C12N-015/85;

C12N-015/86; C12N-015/09; C12R-001-91

File Segment: CPI

Manual Codes (CPI/A-N): B04-E08; B14-S03; D05-H12E; D05-H14B Chemical Fragment Codes (M1):

01 M423 M720 M903 N131 N132 N135 P210 P220 P330 Q233 V753

02 M423 M710 M903 N135 Q233 V500 V540 V550

03 M423 M720 M903 N131 N132 N135 P633 Q233 V600 V613 V791 V802 V803 V810

<Image 1 (6.07\ X 3.62\) is available via Offline Print to STP, NOW, and FAX>

END OF DOCUMENT

EP 254315 B1 E 27

```
(c) 1999 Derwent Info Ltd. All rights reserved.
  Plasmids contg. autonomously replicating sequence DNA - useful for
 producing proteins
Patent Assignee: DAIICHI PHARM CO LTD (DAUC ); DAIICHI SEIYAKU CO (DAUC )
Inventor: ARIGA H
Number of Countries: 014
  Number of Patents: 009
Patent Family:
Patent No Kind Date Applicat No Kind Date Main IPC
                                                         Week
EP 254315 A 19880127 EP 87110696 A 19870723
                                                          198804 B
JP 63185386 A 19880730 JP 87184749 A 19870724
                                                          198836
US 5364761 A 19941115 US 8777467 A 19870724 C12Q-001/68 199445
US 90545675 A 19900629
US 92972089 A 19921105
EP 254315 B1 19960327 EP 87110696 A 19870723 C12N-015/10 199617
DE 3751757 G 19960502 DE 3751757 A 19870723 C12N-015/10 199623
EP 87110696 A 19870723
ES 2091179 T3 19961101 EP 87110696 A 19870723 C12N-015/10 199650
JP 9227598 A 19970902 JP 87184749 A 19870724 C07K-014/47 199745
JP 96278742 A 19870724
JP 2700458 B2 19980121 JP 87184749 A 19870724 C12N-015/09 199808
JP 2798660 B2 19980917 JP 87184749 A 19870724 C12P-021/02 199842
JP 96278742 A 19870724
Priority Applications (No Type Date): JP 86227455 A 19860926; JP 86174036 A
19860724
Cited Patents: 6.Jnl.Ref; A3...8950; EP 240373; EP 45573; No-SR.Pub
Patent Details:
Patent Kind Lan Pg Filing Notes Application Patent
EP 254315 A E 17
 Designated States (Regional): AT BE CH DE ES FR GB GR IT LI NL SE
US 5364761 A 11 Cont of US 8777467
        US 90545675
Cont of
```

Designated States (Pegional): Am product room of on on the transfer

Abstract (Basic): EP 254315 A

Novel plasmid contains a mammalian cell-derived autonomously replicating sequence DNA (I), a promoter and a gene for peptide prodn. inclusive of the translation initiation codon. (I), having affinity for DNA-binding protein (II), is claimed per se. (I) may be recovered by binding a mammalian cell-derived DNA fragment to (II), sepg. the bound DNA fragment/myc protein prod. and isloating the DNA.

USE/ADVANTAGE - The plasmid contg. (I) may be used to transfect cells for prodn. of proteins, such as insulin, growth hormone, interferons, tumour necrosis factor, interleukins, lymphokines and enzymes. The cells into which the plasmid is introduced need not be of the same species as that from which (I) is derived.

0/8

Abstract (Equivalent): EP 254315 B

A method of recovering a mammalian cell-derived autonomously replicating sequence (ARS) DNA fragment which comprises binding a mammalian cell-derived DNA fragment to a DNA-binding protein, separating the DNA/DNA-binding protein complex and isolating the DNA from said DNA/DNA-binding protein complex, wherein th DNA-binding protein is selected from the group, consisting of myc proteins, c-myb protein, v-myb protein, c-fos protein, v-fos protein and p 53, and wherein the ARS DNA originates from a mammalian cell line producing said DNA-binding protein at a high level.

Dwq.0/6

Abstract (Equivalent): US 5364761 A

Recovering a DNA fragment contg. an autonomously replicating sequence comprises binding N-myc, p53 or c-myc proteins to a human cell-derived DNA fragment, sepg. the bound product and isolating DNA with autonomously replicating activity.

USE - Prodn. of peptides.

Dwq.0/4

Title Terms: PLASMID; CONTAIN; AUTONOMOUS; REPLICA; SEQUENCE; DNA; USEFUL; PRODUCE; PROTEIN

Derwent Class: B04; D16

International Patent Class (Main): C07K-014/47; C12N-015/09; C12N-015/10; C12O-001/68

International Patent Class (Additional): C07H-021/04; C12N-005/00; C12N-005/10; C12N-005/16; C12N-015/00: C12N-015/11: C12N-015/00:

Chemical Fragment Codes (MI):

01 M421 M423 M710 M720 M903 N131 N134 N135 N136 N512 N513 Q233 V275 V600 V624 V641 V752 V753 V602 V613 V3

02 F012 F014 F423 F521 G010 G013 G100 H1 H100 H101 H181 H182 H4 H401 H441 H481 H8 J0 J011 J012 J1 J111 J171 J172 J3 J371 K0 K2 K224 L2 L250 M280 M311 M312 M313 M314 M315 M320 M321 M322 M331 M332 M333 M340 M342 M343 M349 M371 M381 M391 M392 M423 M510 M520 M521 M530 M531 M540 M620 M720 M903 M904 M910 N131 N134 N135 N136 N512 N513 Q233 V0 V621 V901 V917 V922 R01851-P

Derwent Registry Numbers: 1851-P Specific Compound Numbers: R01851-P

END OF DOCUMENT